Search:

Login | Subscribe

Home > Companies > Plethora Solutions...

Price	Market	Sector	Market Cap
18.00p (0.00p) 0.00%	AIM	Medicine and Biotech Research	£5.04m

Add to company folder | Print

Related Companies

AGY	10.00p	0.00%
APH	4.62p	0.00%
AZH	p
BBI	p
CEN	p
CBF	2.00p	0.00%
COT	91.50p	-0.54%
CRX	2.62p	0.00%
CYX	p
LAC	p
EVC	25.75p	0.00%
FUL	3.12p	0.00%
FUM	27.25p	-0.91%
GMX	1.75p	0.00%
GNI	p
GWP	29.50p	-0.84%
HML	0.42p	0.00%
MLR	p
MMG	7.25p	0.00%
MPM	9.75p	5.41%

Commentary

Pharmaceuticals developer focusing on urological disorders

Recent Articles

EU trial cheers Plethora	07/11/2008
Plethora Solutions	25/05/2007
Maelor slashes interim loss	02/11/2006
Cardpoint crashes as Plethora leaps	02/12/2005
Plethora spurts up	02/12/2005
Newcomer - Plethora Solutions Holdings	10/05/2005

Recent Announcements

Holding(s) in Company	14/11/2008
ErecAid Study Results	14/11/2008
Phase III European Clinical Trial Results PSD502	07/11/2008
Interim Results	30/09/2008
Clinical Update - PSD502	30/09/2008
Board Change	11/08/2008
Holding(s) in Company	21/07/2008
Director/PDMR Shareholding	01/07/2008
Change of Adviser	01/07/2008
Board Change	27/06/2008
More

Articles from the Sector

Stroke hope at ReNeuron	28/11/2008
Futura Medical	28/11/2008
Option deal boosts ImmuPharma	25/11/2008
Digital imager targets AIM	24/11/2008
Vectura loses interim £11.7m	24/11/2008
GW trims loss	19/11/2008
Asterand	18/11/2008
IS Pharma	05/11/2008
Animalcare nurturing high-margin growth	03/11/2008
Phynova hails pre-clinical cheer	22/10/2008
More

Financial History

Financial Year End	31/12/2004	31/12/2005	31/12/2006	31/12/2007
Currency	GBP	GBP	GBP	GBP
Turnover	0.00	0.02	5.16	5.77
Operating Profit	-2.65	-6.00	-6.49	-10.98
Pretax Profit	-2.76	-5.80	-6.24	-11.24
Earnings After Tax	-2.76	-5.66	-5.89	-10.48
Profit Available For Dividend	0.00	0.00	0.00	0.00
Ordinary Dividends	0.00	0.00	0.00	0.00
Retained Profit	0.00	-5.66	0.00	0.00
Shareholders Funds	-1.76	5.76	7.37	1.67
Net Current Assets	-1.81	5.68	0.00	0.00
Adjusted Earnings Per Share Undiluted	0.00	0.00	-23.30	-38.40
Adj Earnings Per Share	0.00	0.00	-23.30	-38.40
Dividend Per Share	0.00	0.00	0.00	0.00

Chart

Click here for interactive charting

Company Details
Address	233 High Holborn, London, WC1V 7DN
Telephone	020 3077 5400
Fax	020 3077 5440
Executives
Chairman	Stuart Wallis (0.00% holding)
Chief Executive	Steven Powell (0.01% holding)
Finance Director	David Ellam (0.00% holding)
Non-Exec Director	Neil Stafford (3.30% holding)
Main Shareholders
	Merlin Biosciences Fund III: 31.2% HSBC Global Custody Nominee UK: 13.8% Sciele Pharma Cayman: 6.3% Merlin Biosciences Fund III GmbH : 5.8%
Advisers
Nominated Adviser	FinnCap
Nominated Broker	Collins Stewart; FinnCap
Solicitors	Morrison & Foerster
Auditors	Grant Thornton
Registrar	Equiniti

Commentary
Pharmaceuticals developer focusing on urological disorders
Company Data
Code	PLE
Sedol	GB00B06GL8
Shares In Issue	28.014 m
Indices	Aim
Entry on AIM	24/03/2005
Interim Results	Sep
Final Results	Apr
Year End	Dec
Accounts Due	May
Int div payment	n/a
Fin div payment	n/a
Int net div per share	nil
Fin net div per share	nil
Probable CGT relief	Yes